MESO
Mesoblast Limited
Mesoblast Limited (MESO) is currently in a range/mixed trend, trading above both the 50-day and 200-day moving averages. RSI is at 77.9 (overbought), with 2/3 trend checks passing.
MESO with MA50 and MA200
Key levels & signals
MESO valuation multiples (TTM)
MESO analyst consensus
Mesoblast Limited (MESO) looks more range-bound than strongly trending, but there are still a few supportive signs on the chart. The latest available price is $19.02, and 2 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 28.2% and above the 200-day moving average by 17.1%.
MESO currently has an RSI reading of 77.9, which points to very strong short-term momentum but also a fairly extended setup. Stocks can stay strong for longer than expected, but this kind of reading often tells beginners not to confuse strength with low-risk entry timing.
Because MESO is showing stronger momentum inside a more extended backdrop, the next step is often about timing rather than direction. A stock can keep pushing higher, but many traders will still watch for whether the move stays orderly or starts to look too stretched to offer a comfortable entry.
About Mesoblast Limited
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
MESO shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about MESO
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.